Ownership Summary
Innate Pharma SA (NASDAQ:IPHA) showed up in the 13F filings of 9 institutional investors as of March 2026.
- Collectively, these holders controlled 0.0% of Innate Pharma's outstanding shares in March 2026, down from 0.0% in December 2025.
- They decreased total shares held in Innate Pharma by -25.78% from last quarter, and the number of investors in IPHA decreased 18.18% annually.
- Of these 9 holders, 1 added to their stakes in Innate Pharma, 6 trimmed positions, and 2 made no changes.
- Combined, these investors held 183.95K shares in IPHA for March 2026, down by 63.89K shares quarter on quarter, and up 20.8K shares year over year.
- Lion Point Capital, LP leads ownership in IPHA with 81.15K shares as of March 31, 2026, equal to 0.0% of outstanding shares.
- The most significant purchases of IPHA for the quarter ending March 2026 came from Caitong International Asset Management Co., Ltd (2).
- Top sellers of IPHA stock for the quarter ending March 2026 included JANE STREET GROUP, LLC (49.39K), MILLENNIUM MANAGEMENT LLC (10.24K), Morgan Stanley (2.87K), GAMMA Investing LLC (833), RHUMBLINE ADVISERS (470).
- According to Business Quant data, leading holders of IPHA for March 2026 are Lion Point Capital, LP (81.15K), Morgan Stanley (43.52K), JANE STREET GROUP, LLC (43.36K), MILLENNIUM MANAGEMENT LLC (10.06K), RHUMBLINE ADVISERS (4.73K), UBS Group AG (861), GAMMA Investing LLC (240), Farther Finance Advisors, LLC (10), Caitong International Asset Management Co., Ltd (2).